Two shadows have recently been cast over the exciting fieldof gene therapy. One was cast by the unfortunate death of an18-year-old man at the University of Pennsylvania in 1999.1The patient was part of a trial in which an adenovirus containinga gene for ornithine transcarbamylase was infused into patientswith partial deficiencies of the enzyme. The death highlightedthe potential dangers of the direct administration of adenovirusesand, perhaps, other viruses to patients. The second shadow wascast by a clinical trial involving children with X-linked severecombined immunodeficiency (SCID).2 The trial had an added measureof . . . [Full Text of this Article]
Source Information
From the Center for Gene Therapy, Tulane University Health Sciences Center, New Orleans.
This article has been cited by other articles:
Bitton, A., Yialamas, M., Levy, B. D., Katz, J. T., Loscalzo, J.
(2009). A Fragile Balance. NEJM
361: 74-79
[Full Text]
Li, Y., Chen, S., Yuan, J., Yang, Y., Li, J., Ma, J., Wu, X., Freund, M., Pollok, K., Hanenberg, H., Goebel, W. S., Yang, F.-C.
(2009). Mesenchymal stem/progenitor cells promote the reconstitution of exogenous hematopoietic stem cells in Fancg-/- mice in vivo. Blood
113: 2342-2351
[Abstract][Full Text]
Ishikawa, F., Shimazu, H., Shultz, L. D., Fukata, M., Nakamura, R., Lyons, B., Shimoda, K., Shimoda, S., Kanemaru, T., Nakamura, K.-i., Ito, H., Kaji, Y., Perry, A. C.F., Harada, M.
(2006). Purified human hematopoietic stem cells contribute to the generation of cardiomyocytes through cell fusion. FASEB J.
20: 950-952
[Abstract][Full Text]
Previous
